Clinical Trials Logo

Alcohol Dependence clinical trials

View clinical trials related to Alcohol Dependence.

Filter by:

NCT ID: NCT06308484 Recruiting - Alcohol Dependence Clinical Trials

Neuromodulation and Mindfulness Patients With AUD

Start date: March 20, 2024
Phase: N/A
Study type: Interventional

Our primary objective is to integrate tVNS and mindfulness meditation within a structured mindfulness-based relapse prevention (MBRP) program for detoxified alcohol-dependent patients (AD). We aim to determine whether neuromodulation can enhance mindfulness-based relapse prevention compared to mindfulness practice alone. In this context, we will investigate potential changes in the interaction of top-down control and cue reactivity, as well as assess the severity of AUD. Measurements of drinking behavior, cravings, and abstinence rates will be conducted up to three months post-treatment. Our second objective is to examine the causal role of frontal midline theta oscillations (FMΘ) in MBRP and cognitive control. To achieve this, we will first establish closed-loop amplitude-modulated transcranial alternating current stimulation (CLAM-tACS) to selectively modulate FMΘ oscillations during MBRP meditation exercises in AUD patients (2).

NCT ID: NCT06265506 Not yet recruiting - Clinical trials for Alcohol Use Disorder

Virtual Incentive Treatment for Alcohol

VITA
Start date: February 19, 2024
Phase: N/A
Study type: Interventional

The overall objective of this program of research is to utilize phosphatidylethanol (PEth), a blood-based biomarker that can detect alcohol use for up to 28 days to deliver a feasible telehealth-based 26-week CM intervention. This study will test a telehealth PEth-based CM model in a sample of adults with AUD (n=200), recruited via online platforms by randomizing individuals to six months of 1) an online cognitive behavioral therapy for AUD (CBT4CBT) and telehealth PEth-based CM (CM condition) or 2) CBT4CBT and reinforcers for submitting blood samples (no abstinence required) (control condition). Investigators will assess group differences in PEth-defined abstinence and regular excessive drinking (PEth >= 200 ng/mL), and alcohol-related harms (e.g., smoking, drug use). This study will address important gaps in CM research by assessing outcomes during a 12-month follow-up, which is much longer than most previous CM studies; using a conceptual model to identify predictors of post-treatment abstinence. Investigators will conduct an economic analysis to place the cost of this model in the context of downstream CM-associated cost-offsets and improvements in personal and public health.

NCT ID: NCT06262958 Recruiting - Clinical trials for Substance Use Disorders

Recognition and Early Intervention for Alcohol and Substance Abuse in Adolescence in Adolescent

REAL-SMART
Start date: August 7, 2017
Phase: N/A
Study type: Interventional

ASSIST mini-intervention is applied in an electric form in adolescent outpatients to see if it

NCT ID: NCT06173973 Not yet recruiting - Clinical trials for Alcohol Use Disorder

Effects of Ketone Supplementation on Acute Alcohol Withdrawal

Start date: March 2024
Phase: Phase 2/Phase 3
Study type: Interventional

The goal of this study is to study the effects of the ketone supplement Kenetik compared to placebo (an inactive beverage) on alcohol withdrawal symptoms during the 5 days of clinical alcohol withdrawal management treatment at the Caron Treatment Center.

NCT ID: NCT05963659 Recruiting - Alcohol Dependence Clinical Trials

Nitrate Modulates Cognitive Impairment Via Oral Microbiota.

Start date: September 10, 2023
Phase: N/A
Study type: Interventional

Alcohol use is increasingly prevalent in modern society and is known to cause cognitive impairment and dysregulation of inflammatory responses. In the present study, the investigators want to perform a randomised controlled trials to test whether nitrate could change the oral microbiota and benefit the cognitive impairment in alcohol dependence patients. The investigators survey the oral bacterial communities in saliva samples of 70 alcohol dependent patients following 14 days of dietary inorganic nitrate (nitrate-rich beetroot juice, ~750 mg NO3- /d) and placebo (nitrate-depleted beetroot juice, ~1 mg NO3- /d) supplementation.

NCT ID: NCT05895643 Recruiting - Clinical trials for Alcohol Use Disorder

Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?

SEMALCO
Start date: June 13, 2023
Phase: Phase 2
Study type: Interventional

This 26-week long, double-blinded randomized clinical trial aims to investigate the effects of the GLP-1 receptor agonist semaglutide s.c. vs placebo on alcohol consumption in 108 patients diagnosed with alcohol use disorder and comorbid obesity (BMI>30 kg/m2). Patients will be treated for 26 weeks with semaglutide subcutaneously (s.c.) once weekly or placebo. The medication will be provided as a supplement to standardised cognitive behavioural therapy. A subgroup of the patients will have two brain scans (Magnetic Resonance Spectroscopy (MRS) and functional Magnetic Resonance Imaging (fMRI)) conducted in one scan session at week 0 and 26. The primary endpoint is the percentage-point reduction in total number of heavy drinking days, defined as days with an excess intake of 48/60 grams of alcohol per day (women and men, respectively) from baseline to follow-up after 26 weeks of treatment, measured by the timeline followback (TLFB) method.

NCT ID: NCT05854693 Recruiting - Alcohol Dependence Clinical Trials

Trans-cranial Direct Current Stimulation on Alcohol Craving

Start date: April 17, 2023
Phase: N/A
Study type: Interventional

The goal of thisclinical trial is to investigate the efficacy of trans cranial direct current stimulation (tDCS) for alcohol craving in individuals with alcohol dependence. The main question it aims to answer is whether 10 sessions of tDCS can reduce craving for alcohol. Participants will be randomized into active group and sham group. Researchers will compare the severity of craving in these groups.

NCT ID: NCT05747703 Not yet recruiting - Clinical trials for Alcohol Use Disorder

Telehealth Treatment for Alcohol Use Disorder

Start date: May 2023
Phase: N/A
Study type: Interventional

Participants with alcohol use disorder will be randomly assigned to either the Ria Treatment Platform or a waitlist control. The Ria Treatment Platform is a telehealth approach that incorporates medical assessment, medications for alcohol use disorder, individual and group coaching, educational video modules, and a Bluetooth-enabled breathalyzer. Patients are followed for three months during which data are collected, including measures of alcohol consumption and its consequences.

NCT ID: NCT05738174 Recruiting - Alcohol Dependence Clinical Trials

High-dose Accelerated Theta Burst Stimulation for the Treatment of Alcohol Addiction

TBA
Start date: March 1, 2023
Phase: N/A
Study type: Interventional

This is a two-arm randomized placebo-controlled trial in which 72 patients with alcohol addiction are treated with high-dose accelerated intermittent theta burst stimulation (TBS).

NCT ID: NCT05709353 Recruiting - PTSD Clinical Trials

MDMA-assisted Prolonged Exposure Therapy for Comorbid Alcohol Use Disorder and Post-traumatic Stress Disorder

MPATHY
Start date: September 19, 2023
Phase: Phase 2
Study type: Interventional

To explore the effectiveness of of MDMA-assisted prolonged exposure therapy in improving treatment outcomes for individuals with comorbid PTSD and alcohol use disorder in a double-blind randomised placebo-controlled trial.